Company Filing History:
Years Active: 2016-2025
Title: Carl-Johan Dalsgaard: Innovator in Pulmonary Treatment
Introduction
Carl-Johan Dalsgaard is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of medicine, particularly in the treatment of idiopathic pulmonary fibrosis. With a total of 6 patents to his name, Dalsgaard's work is recognized for its innovative approaches to complex health issues.
Latest Patents
One of Dalsgaard's latest patents focuses on the treatment of idiopathic pulmonary fibrosis. The invention provides a method for improving or restoring function in patients suffering from this condition. This method involves the peroral administration of a therapeutically effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof. The treatment is capable of addressing idiopathic pulmonary fibrosis in a therapeutic, and potentially curative, manner.
Career Highlights
Throughout his career, Dalsgaard has worked with various companies, including Vicore Pharma AB and Rspr Pharma AB. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.
Collaborations
Dalsgaard has collaborated with notable professionals in his field, including Rohit Batta and Johan Raud. These partnerships have further enhanced his research and development efforts, leading to impactful innovations.
Conclusion
Carl-Johan Dalsgaard stands out as a significant figure in the realm of medical innovation, particularly in the treatment of idiopathic pulmonary fibrosis. His contributions through patents and collaborations continue to influence the field positively.